Aurélien Marabelle

37.8k total citations · 12 hit papers
281 papers, 15.2k citations indexed

About

Aurélien Marabelle is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Aurélien Marabelle has authored 281 papers receiving a total of 15.2k indexed citations (citations by other indexed papers that have themselves been cited), including 227 papers in Oncology, 100 papers in Immunology and 43 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Aurélien Marabelle's work include Cancer Immunotherapy and Biomarkers (189 papers), CAR-T cell therapy research (65 papers) and Immunotherapy and Immune Responses (60 papers). Aurélien Marabelle is often cited by papers focused on Cancer Immunotherapy and Biomarkers (189 papers), CAR-T cell therapy research (65 papers) and Immunotherapy and Immune Responses (60 papers). Aurélien Marabelle collaborates with scholars based in France, United States and Spain. Aurélien Marabelle's co-authors include Stéphane Champiat, Jean‐Charles Soria, Laurence Zitvogel, Christophe Massard, Guido Kroemer, Roch Houot, Samy Ammari, Holbrook E. Kohrt, Alexander Eggermont and Sophie Postel‐Vinay and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Aurélien Marabelle

269 papers receiving 15.0k citations

Hit Papers

Targeting the tumor microenvironment: removing obstructio... 2016 2026 2019 2022 2016 2016 2018 2016 2022 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
    2016 976 citations Jonathan M. Pitt, Aurélien Marabelle et al. Annals of Oncology profile →
  2. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
    2016 867 citations Stéphane Champiat, Laurent Dercle et al. Clinical Cancer Research profile →
  3. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
    2018 825 citations Laurent Dercle, Stéphane Champiat et al. profile →
  4. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
    2016 813 citations Olivier Lambotte, Aurélien Marabelle et al. Nature Reviews Clinical Oncology profile →
  5. Cancer vaccines: the next immunotherapy frontier
    2022 553 citations Aurélien Marabelle, Ignacio Melero et al. Nature Cancer profile →
  6. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
    2018 376 citations Jean‐Marie Michot, Stéphane Champiat et al. profile →
  7. Intratumoural administration and tumour tissue targeting of cancer immunotherapies
    2021 342 citations Ignacio Melero, Eduardo Castañón et al. Nature Reviews Clinical Oncology profile →
  8. Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
    2022 273 citations David M. O’Malley, Giovanni M. Bariani et al. Journal of Clinical Oncology profile →
  9. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
    2019 272 citations Jean‐Marie Michot, Ariane Laparra et al. profile →
  10. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
    2022 240 citations Michele Maio, Paolo A. Ascierto et al. Annals of Oncology profile →
  11. Tumour burden and efficacy of immune-checkpoint inhibitors
    2021 209 citations Aurélien Marabelle, Caroline Caramella et al. Nature Reviews Clinical Oncology profile →
  12. Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
    2021 196 citations Aurélien Marabelle, Fabrice Barlési et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aurélien Marabelle France 63 10.2k 5.8k 3.1k 2.8k 1.7k 281 15.2k
Patrick A. Ott United States 57 11.3k 1.1× 5.6k 1.0× 3.5k 1.1× 3.6k 1.3× 813 0.5× 240 15.6k
José Luis Perez‐Gracia Spain 51 10.4k 1.0× 5.7k 1.0× 5.0k 1.6× 2.8k 1.0× 721 0.4× 191 15.2k
Axel Hoos United States 55 9.2k 0.9× 4.7k 0.8× 2.8k 0.9× 3.4k 1.2× 1.1k 0.7× 142 13.4k
Leisha A. Emens United States 52 10.7k 1.1× 6.0k 1.0× 3.1k 1.0× 2.9k 1.0× 1.0k 0.6× 166 14.5k
Mario Sznol United States 67 13.8k 1.4× 7.8k 1.3× 4.3k 1.4× 5.6k 2.0× 981 0.6× 270 19.8k
Daniel S. Chen United States 29 13.3k 1.3× 8.5k 1.5× 4.6k 1.5× 5.1k 1.8× 1.1k 0.6× 50 20.1k
Sandra Demaria United States 65 14.7k 1.4× 10.6k 1.8× 4.8k 1.5× 3.6k 1.3× 2.9k 1.7× 192 21.7k
Michele Maio Italy 66 11.4k 1.1× 6.9k 1.2× 3.3k 1.1× 7.3k 2.7× 1.1k 0.7× 376 18.5k
James L. Gulley United States 71 11.7k 1.1× 8.3k 1.4× 5.7k 1.8× 4.2k 1.5× 1.9k 1.1× 568 18.4k
Michele W.L. Teng Australia 56 9.2k 0.9× 8.3k 1.4× 1.9k 0.6× 3.6k 1.3× 588 0.3× 95 15.0k

Countries citing papers authored by Aurélien Marabelle

Since Specialization
Citations

This map shows the geographic impact of Aurélien Marabelle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurélien Marabelle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurélien Marabelle more than expected).

Fields of papers citing papers by Aurélien Marabelle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aurélien Marabelle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurélien Marabelle. The network helps show where Aurélien Marabelle may publish in the future.

Co-authorship network of co-authors of Aurélien Marabelle

This figure shows the co-authorship network connecting the top 25 collaborators of Aurélien Marabelle. A scholar is included among the top collaborators of Aurélien Marabelle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurélien Marabelle. Aurélien Marabelle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marabelle, Aurélien, David M. O’Malley, Andrew Hendifar, et al.. (2025). Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. Nature Cancer. 6(2). 253–258. 2 indexed citations
2.
Laparra, Ariane, Stéphane Champiat, François‐Xavier Danlos, et al.. (2025). Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 13(9). e012756–e012756.
3.
Chung, Rainjade, James M. McKiernan, Nicholas Arpaia, Aurélien Marabelle, & Mathieu Rouanne. (2023). Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity. European Journal of Cancer. 187. 58–64. 7 indexed citations
4.
5.
Gazzah, Anas, Ratislav Bahleda, Antoine Hollebecque, et al.. (2023). Profile and outcome of cancer patients enrolled in contemporary phase I trials. European Journal of Cancer. 188. 1–7. 2 indexed citations
6.
Goldman, Jonathan W., Sarina A. Piha‐Paul, Brendan D. Curti, et al.. (2022). Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 28(17). 3709–3719. 19 indexed citations
7.
Tselikas, Lambros, Stéphane Champiat, Rahul A. Sheth, et al.. (2021). Interventional Radiology for Local Immunotherapy in Oncology. Clinical Cancer Research. 27(10). 2698–2705. 26 indexed citations
8.
Melero, Ignacio, Eduardo Castañón, Maite Álvarez, Stéphane Champiat, & Aurélien Marabelle. (2021). Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nature Reviews Clinical Oncology. 18(9). 558–576. 342 indexed citations breakdown →
9.
Baldini, Capucine, P. Martin Romano, Anne-Laure Voisin, et al.. (2020). Impact of aging on immune-related adverse events generated by anti–programmed death (ligand)PD-(L)1 therapies. European Journal of Cancer. 129. 71–79. 63 indexed citations
10.
Gauci, Marie-Léa, Émilie Lanoy, Stéphane Champiat, et al.. (2018). Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research. 25(3). 946–956. 106 indexed citations
11.
Geoerger, Birgit, Franck Bourdeaut, Steven G. DuBois, et al.. (2017). A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical Cancer Research. 23(10). 2433–2441. 121 indexed citations
12.
Fend, Laetitia, Takahiro Yamazaki, Murielle Gantzer, et al.. (2017). Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. Cancer Research. 77(15). 4146–4157. 108 indexed citations
13.
Pitt, Jonathan M., Aurélien Marabelle, Alexander Eggermont, et al.. (2016). Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Annals of Oncology. 27(8). 1482–1492. 976 indexed citations breakdown →
14.
Jacquelot, Nicolas, David Enot, Sylvie Rusakiewicz, et al.. (2016). Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. Journal of Investigative Dermatology. 136(5). 994–1001. 22 indexed citations
15.
Champiat, Stéphane, Laurent Dercle, Samy Ammari, et al.. (2016). Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clinical Cancer Research. 23(8). 1920–1928. 867 indexed citations breakdown →
16.
Vences‐Catalán, Felipe, Ranjani Rajapaksa, Minu K. Srivastava, et al.. (2015). Tetraspanin CD81 Promotes Tumor Growth and Metastasis by Modulating the Functions of T Regulatory and Myeloid-Derived Suppressor Cells. Cancer Research. 75(21). 4517–4526. 67 indexed citations
17.
Vacchelli, Erika, Jonathan Pol, Norma Bloy, et al.. (2015). Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. OncoImmunology. 4(1). e985940–e985940. 40 indexed citations
18.
Marabelle, Aurélien, Holbrook E. Kohrt, & Ronald Levy. (2014). New insights into the mechanism of action of immune checkpoint antibodies. OncoImmunology. 3(8). e954869–e954869. 9 indexed citations
19.
Kohrt, Holbrook E., Ariane Thielens, Aurélien Marabelle, et al.. (2013). Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 123(5). 678–686. 229 indexed citations
20.
Labrousse, François, et al.. (2011). Clear cell ependymoma with trisomy 19 developing bone metastases. Child s Nervous System. 28(5). 739–742. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick A. Ott Breakdown of academic impact, for papers by José Luis Perez‐Gracia Breakdown of academic impact, for papers by Axel Hoos Breakdown of academic impact, for papers by Leisha A. Emens Breakdown of academic impact, for papers by Mario Sznol Breakdown of academic impact, for papers by Daniel S. Chen Breakdown of academic impact, for papers by Sandra Demaria Breakdown of academic impact, for papers by Michele Maio Breakdown of academic impact, for papers by James L. Gulley Breakdown of academic impact, for papers by Michele W.L. Teng
Rankless by CCL
2026